Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION Breast02
jRCT2061220029Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan in triple-negative breast cancer (TNBC) and breast cancer, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Progression-free survival and Overall survival. Started Jun 2022; status: active, not recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on jRCT2061220029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220029.